Introduction
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy.
The target population of interest in this study consists of patients with ER+/HER2- early breast cancer, who have completed definitive locoregional therapy and at least 2 years of standard adjuvant ET, with or without a cyclin dependent kinase 4 and 6 (CDK4/6) inhibitor, and who are currently disease-free but with intermediate or high risk of recurrence.
News
We are still looking for patients for this study. You are welcome to make a referral to one of our trial centers. We gladly inform you of the nearest trial center by email.
The inclusion and exclusion criteria can be found on ClinicalTrials.gov. More detailed information on the study design can be found in the synopsis.
Design
Primary Efficacy
Comparison of IBCFS (invasive breast cancer-free survival) rates by treatment
Patient Profile
- Early ER+/HER2- breast cancer with no disease recurrence
- Pre-, Peri-, and postmenopausal Women and Men
- Adequate surgical and systemic pre-therapy with or without chemotherapy or radiotherapy
- At least 2 years and up to 5 years of standard adjuvant ET
- Patients may have received adjuvant CDK4/6 inhibitors prior to study entry
- Intermediate or high risk of recurrence as defined per protocol
Contact
Anna Huber
